« Zurück
Startseite /
Pexidartinib (hydrochloride)

Pexidartinib (hydrochloride)

ArtNr	HY-16749A-50mg
Hersteller	MedChem Express
CAS-Nr.	2040295-03-0
Menge	50 mg
Quantity options	10 g 10 mM/1 mL 10 mg 1 g 200 mg 20 g 2 g 500 mg 50 mg 5 g 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.86
Citations	[1]DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun;1(1):54-67.\|[2]Kuse Y, et al. Microglia increases the proliferation of retinal precursor cells during postnatal development. Mol Vis. 2018 Jul 30;24:536-545. eCollection 2018.\|[3]Lee JH, et al. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2019 Mar 2.\|[4]Merry TL, et al. The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice. Int J Obes (Lond). 2020;44(1):245-253.\|[5]Luo L, et al. Intermittent theta-burst stimulation improves motor function by inhibiting neuronal pyroptosis and regulating microglial polarization via TLR4/NFκB/NLRP3 signaling pathway in cerebral ischemic mice. J Neuroinflammation. 2022 Jun 11;19(1):141.\|[6]Chadarevian JP, et al. Engineering an inhibitor-resistant human CSF1R variant for microglia replacement. J Exp Med. 2023 Mar 6;220(3):e20220857. Autophagy. 2025 Mar 19:1-21.\|Biomolecules. 2022 May 4;12(5):666.\|Universität zu Köln. 2023 Sep 26.\|ACS Nano. 2024 Jan 22.\|Adv Sci (Weinh). 2024 Dec 12:e2413451.\|Adv Sci (Weinh). 2024 Dec 5:e2410360.\|Am J Physiol Cell Physiol. 2020 Sep 1;319(3):C605-C610.\|Anti-Cancer Drug. 2022 Dec.\|Behav Pharmacol. 2023 Sep 1;34(6):318-329.\|Biochem Pharmacol. 2022 Feb 9;198:114952.\|Biomedicines. 2021, 9(10), 1387.\|Biomedicines. 2022, 10(7), 1653.\|bioRxiv. 2023 Jul 25.\|bioRxiv. 2023 Nov 14.\|bioRxiv. 2023 Nov 17.\|bioRxiv. 2023 Oct 12.\|bioRxiv. 2024 Apr 14.\|bioRxiv. 2024 Apr 16.\|biorxiv. 2024 Jun 06.\|bioRxiv. 2024 October 02.\|bioRxiv. 2024 September 21.\|bioRxiv. 2025 Jan 19:2025.01.19.633810.\|BMC Med. 2023 Aug 4;21(1):286.\|Brain Behav Immun. 2022 Oct 3;S0889-1591(22)00398-1.\|Brain Behav. 2025 Mar;15(3):e70369.\|Cancer Cell. 2021 Sep 1;S1535-6108(21)00445-1.\|Cancer Cell. 2023 Nov 13;41(11):1911-1926.e8.\|Cancer Lett. 2022 Jun 16;215795.\|Cell Oncol. 2021 Feb;44(1):193-204.\|Cell Rep. 2023 Sep 22;42(10):113128.\|Cell Rep. 2024 Oct 23;43(11):114894.\|Cell Stem Cell. 2024 Oct 30:S1934-5909(24)00367-9.\|Cells. 2021, 10(4), 874.\|Cells. 2021, 10(8), 1862\|Chem Biol Interact. 2022: 110255.\|Circ Res. 2021 Sep 17;129(7):e121-e140.\|CNS Neurosci Ther. 2023 Mar 16.\|Dev Cell. 2024 Dec 30:S1534-5807(24)00736-6. \|Diabetes. 2023 Sep 8;db230173.\|EMBO Mol Med. 2024 Nov 11.\|Endocrinology. 2024 Jan 16:bqae003.\|eNeuro. 2023 Oct 27:ENEURO.0323-23.2023.\|Eur J Immunol. 2024 Sep 23:e2451139.\|Front Immunol. 2022 May 13;13:866073.\|Glia. 2021 Apr;69(4):943-953.\|Glia. 2021 Feb 15.\|Glia. 2022 Jun 30.\|Inflamm Regen. 2024 Jun 6;44(1):30.\|Int Immunopharmacol. 2023 May.\|Int Immunopharmacol. 2025 Mar 11:152:114428.\|Int J Mol Sci. 2024 Jun 26;25(13):7001.\|Interdiscip Med. 2025 Feb 24.\|Invest Ophthalmol Vis Sci. 2025 Mar 3;66(3):4.\|J Am Heart Assoc. 2023 Jun 15;e029053.\|J Anat. 2023 Apr 11.\|J Ethnopharmacol. 2025 Jan 31:340:119287.\|J Exp Med. 2023 Mar 6;220(3):e20220857.\|J Neuroinflammation. 2020 Jan 23;17(1):31.\|J Neuroinflammation. 2022 Jan 21;19(1):20.\|J Neuroinflammation. 2023 Feb 25;20(1):51.\|J Neuroinflammation. 2024 Nov 14;21(1):295.\|J Neuroinflammation. 2024 Oct 21;21(1):270.\|J Neuroinflammation. 2024 Sep 01.\|J Neuroinflammation. 2025 Mar 5;22(1):67.\|J Neurooncol. 2021 May 8.\|J Neurosci Res. 2021 Feb 20.\|J Neurosci. 2020 May 6;40(19):3862-3879.\|J Ocul Pharmacol Ther. 2020 Jun;36(5):311-319.\|Karolinska Institutet. Dept of Clinical Neuroscience. 2021 Feb.\|Life Sci Alliance. 2023 Aug 7;6(11):e202302020.\|Life Sci. 2020 Oct 1;258:118099.\|Methods Mol Biol. 2018;1711:351-398.\|Mol Pharmacol. April 5, 2022.\|Molecules. 2022, 27(1), 297.\|Nat Biomed Eng. 2018 Aug;2(8):578-588.\|Nat Cardiovasc Res. 2023 Jun 8.\|Nat Commun. 2024 Jul 5;15(1):5654.\|Nat Commun. 2024 Oct 13;15(1):8837.\|Nat Immunol. 2023 May;24(5):827-840.\|Nat Metab. 2024 Jul 24.\|Nature. 2022 Mar;603(7899):138-144.\|Nature. 2024 Apr;628(8006):145-153.\|Neural Regen Res. 2023.\|Neuron. 2021 Aug 18;109(16):2573-2589.e9.\|Neuropharmacology. 2019 Apr 4;151:33-44.\|Neuropharmacology. 2020 Aug 1;172:108132.\|Patent. US20230203500A1.\|Patent. US20250002920A1.\|Pharmacol Res. 2023 Apr 15;106773.\|Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109931.\|Res Sq. 2024 Nov 19.\|Res Sq. 2024 Sep 03.\|Research Square Preprint. 2021 Sep.\|Research Square Preprint. 2022 Jul.\|Research Square Preprint. 2023 Sep 12.\|Research Square Preprint. 2024 Feb 15.\|Research Square Print. 2022 Jun.\|Sci Rep. 2021 Aug 6;11(1):15989.\|Sci Rep. 2024 Aug 4;14(1):18031.\|SSRN. 2023 Jun 29.\|STAR Protoc. 2023 Jul 29;4(3):102490.\|The Ohio State University. 2023 Oct.\|Theranostics. 2020 Jan 1;10(1):74-90.\|Transl Psychiatry. 2020 Jan 27;10(1):32.\|Transl Psychiatry. 2024 Aug 23;14(1):338.\|Transl Stroke Res. 2024 Aug 5.\|Universität zu Köln. 2023 Sep 26.\|University of Washington. 2024.
Smiles	FC(C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C43)C=C2)C=N1)(F)F.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PLX-3397 (hydrochloride)
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; c-Fms; c-Kit
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	454.28
Product Description	Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 60 mg/mL (ultrasonic)\|H2O: < 0.1 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Protein Tyrosine Kinase/RTK
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-16749A-50mg-safety-datasheet.pdf